GlassScriptPhysician profile
Harminder K Atwal
NPI 1134427719
$574.86
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $560 · 2024: $14.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.87 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $89.04 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $51.03 | 2023 | Keytruda |
| Gilead Sciences, INC. | $43.60 | 2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $36.64 | 2023 | Enhertu, Lynparza |
| Celgene Corporation | $33.75 | 2023 | Reblozyl, Opdualag |
| Boston Scientific Corporation | $32.11 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $30.52 | 2023 | Qinlock |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2023 | Ninlaro |
| Genzyme Corporation | $24.64 | 2023 | |
| Stemline Therapeutics INC. | $23.20 | 2023 | Orserdu |
| Daiichi Sankyo INC. | $22.97 | 2023 | Enhertu |
| Lilly USA, LLC | $22.17 | 2023 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $20.34 | 2023 | |
| Genentech USA, INC. | $19.27 | 2023 | Venclexta |
| Astellas Pharma US INC | $17.96 | 2023 | Xospata |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $17.44 | 2023 | |
| Abbvie INC. | $17.04 | 2023 | |
| Eisai INC. | $16.87 | 2023 | |
| Janssen Biotech, INC. | $13.46 | 2023 | Darzalex, Tecvayli |
| Seagen INC. | $13.16 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harminder Atwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.